Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...

Eli Lilly and Company discovers, develops ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Key research pitching the drugs against each other found Mounjaro was superior when it came to shedding pounds and losing ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer, effective on June 9. Rodriguez will report to Jennifer Oleksiw, SVP and global chief customer officer ...